This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
June 18, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook GATC’s MAT platform identifies potential new drugs and provides comprehensive analytic reports. Lisata Therapeutics has formed a strategic partnership with GATC Health to advance AI-driven drug discovery and development.
As formulators, we are often able to directly impact the amount of drug absorbed through formulation optimization and improve exposure. However, the chances of improving the exposure profile of a drug that is highly cleared by formulation modification are limited.
Particularly beneficial in the early drug discovery phase, AI can help identify potential drug targets more effectively than traditional methods, accelerating the initial stages of drugdevelopment by quickly sifting through large volumes of data. You will receive an email shortly.
Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial (..)
A month and a half after winding operations and laying off almost all its staff, Vor Bio has emerged from the brink with a licensing deal potentially rising to $4bn for an autoimmune drugdeveloped by Chinese biotech RemeGen. Give your business an edge with our leading industry insights.
wants to ensure the ensuing the US does not lag behind other countries in drugdevelopment. We want to make sure we are getting rid of the regulatory impediments [that stop drugs getting to market],” RFK Jr stated. Tasos Katopodis / Stringer via Getty Images. Give your business an edge with our leading industry insights.
Actio Biosciences CEO and co-founder David Goldstein stated: “We have made tremendous progress across our pipeline – executing a precision medicine strategy that targets the root causes of disease through genetically informed drugdevelopment. Give your business an edge with our leading industry insights.
Kisunla and Leqembi were touted as the most promising treatments to emerge from Alzheimer’s drugdevelopment in recent times. However, side effects from the drugs can be serious, and their high cost has been a barrier to reimbursement. Give your business an edge with our leading industry insights.
Syngene’s expertise in the field is covered in this whitepaper. “SIM0505 is a significantly differentiated CDH6 targeting ADC candidate independently developed by Simcere Zaiming. In January 2025, AbbVie and Simcere Zaiming entered an option-to-license agreement for the development of SIM0500.
Experts also emphasised that the secondary data will help with accelerating drugdevelopment cycles, making clinical trials more cost-efficient, and improving real-world insights. The more data these digital twins rely on, the more patients you can mirror and the more accurate they will become.”
Outsourcing is now a fundamental part of drugdevelopment and distribution. Navigating customs complexities to ensure the timely and secure delivery of pharma shipments is just one area of expertise, which also include regulatory contingencies, packaging for specific temperatures, and working around challenging regional infrastructure.
Experts praise the reforms to rare disease and antimicrobial research, but they worry that some provisions in the EU Pharma Package may harm innovation on the continent, contrary to its stated objectives. Go deeper with GlobalData Reports Chemotherapy in Pharmaceuticals: Platinum-based cancer drug composi.
A vitally important assay used across various stages of drugdevelopment and manufacturing, container closure integrity testing (CCIT) involves evaluating packaging systems to determine their ability to protect the stability and sterility of pharmaceutical products. The evolution of CCIT.
10 Diagnostics and biologics also heavily utilise carbon-based materials as constituting building blocks, processing aids, single-use reactors, or packaging materials. He is currently group leader of the Technology Development and Discovery Group at the Bioprocess Laboratory of the ETH. EFPIA WhitePaper on Circular Economy, June 2020.
We source as much of the materials as we possibly can locally, even packaging,” he notes. When we need new packaging, it is really simple to get and it is quick. To learn more about the development and partnership opportunities for businesses within Scotland’s health sector, download the document on this page. Free Whitepaper.
In recent years, the pharmaceutical industry has exhibited a significant shift into digitalisation, with AI pushing for innovation across the entire drugdevelopment value chain, from accelerating drug discovery to optimising clinical trial design to ultimately improve patient outcomes.
July 7, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The early stages of formulation development and analytical testing can be some of the most exciting phases of drugdevelopment, fueled by the anticipation that follows the discovery of a promising new active pharmaceutical ingredient (API) or combination.
TEV-56278 demonstrates the strength of Teva’s innovative drugdevelopment capabilities and how strategic partnerships with companies such as Fosun Pharma play a pivotal role in advancing therapies on behalf of patients.” ” TEV-56278 has been specifically engineered to target PD-1 + T cells selectively.
“The integration of genomic data into routine care, combined with streamlined access to clinical trials via the NHS App, has the potential to accelerate drugdevelopment, reduce health inequalities, and unlock new models of preventative care.” How will RFK Jr’s American dream for vaccines play out?
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content